Insulin resistance is a feature of most patients with type 2 diabetes mellitus. Epidemiological evidence suggest a correlation between inflammation and insulin resistant states such as obesity, but the underlying mechanisms are largely unknown. Interleukin-1 receptor-associated kinases (IRAK) play a central role in inflammatory responses by regulating the expression of various inflammatory genes in immune cells. This study was aimed to investigate the effect of IRAK inhibitor on gene transcription and serum concentration of adiponectin in insulin-resistant mice.
degenerative disease, hypertension, hyperglycemia, and metabolic syndrome (1) and even some physiological conditions, such as pregnancy (2) .
Obesity, characterized as a state of chronic low-grade inflammation caused by over-nutrition, is a major cause of decreased insulin sensitivity, which makes obesity a major risk factor for IR (1) . Adiponectin, an adipocyte-specific secretory protein carrying 244 amino acids with 18 signal residues (4) is an adipokine that is specifically and abundantly expressed in adipose tissue, and directly sensitizes the body to insulin. The adiponectin receptors, AdipoR1 and AdipoR2, which mediate the antidiabetic metabolic actions of adiponectin, have been cloned, and are downregulated in obesity-linked IR (5) .
Adiponectin, the adipocyte hormone with the highest plasma concentration, is considered a modulator of carbohydrate and lipid metabolism and a marker of insulin sensitivity. Although mainly produced in adipose tissue, serum adiponectin concentrations are negatively correlated with the amount of visceral adiposity (6) .
Numerous clinical studies demonstrated an inverse relationship between serum adiponectin levels and overproduction of pro-inflammatory markers such as TNF-α and CRP (7) . Given that IL-6 is pro-inflammatory, it is widely accepted that like TNF-α, IL-6 negatively impacts obesityinduced IR (8) .
Thiazolidinediones, including pioglitazone, constitute a new class of oral antidiabetic drugs that are widely used as insulin-sensitizing agents through the activation of PPAR-γ, thereby regulating the transcription of specific genes involved in adipogenesis and IR (9) . IRAK inhibitor can suppress the inflammation pathways and may therefore increase adiponectin expression and secretion by decreasing the level of pro-inflammatory cytokines. Thereupon, we aimed to evaluate the adiponectin gene expression level under treatment with IRAK inhibitor.
Materials and methods

Animals
In According to the similarity of PCR efficiency for adiponectin and GAPDH, difference in gene expression was calculated by 2 -∆∆CT method.
Primer sequences are described in Table 1 (Pishgam Biotech Co, Iran).
Statistical analysis:
All data were analyzed using SPSS software, 
Results
Transcription level of adiponectin gene
RT-qPCR results showed that IRAK inhibitor significantly increased the expression of adiponectin gene (P<0.0001). Also, pioglitazone increased adiponectin gene expression (P=0.0027), although these agents did not show any incremental effect on each other. Results of adiponectin gene expression evaluation are summarized in figure 1 . 
Adiponectin serum concentration
HOMA-AD: Index of insulin sensitivity
As shown in figure 3, HOMA-AD was 0.33±0.04 in pioglitazone treated group, 0.6±0.13 in IRAK inhibitor group, and 0.31±0.03 in animals that received IRAKi and pioglitazone. These results were significantly lower than the control group (2.27±0.28, P<0.0001). HOMA-AD in healthy animals was 0.10±0.007 that is indicative of high insulin sensitivity of these animals.
HOMA-IR and adiponectin correlation
There was a significant (P<0.0001) and
negative correlation (correlation coefficient=-0.527) between adiponectin concentration and HOMA-IR (figure 4) shows this correlation.
Discussion
In obesity state, adipose tissue is developed and its macrophages are increased. Low-grade inflammation increases blood free fatty acid levels which results from obesity, and can induce IR and type 2 diabetes (16, 17) . Obesity also is related to a decrease of adiponectin concentration. Adiponectin is an insulin sensitizer adipokine (18) . IRAK inhibitor, as an interference in inflammation pathways, can increase insulin sensitivity.
Therefore, we evaluated the effects of this factor in comparison with pioglitazone on adiponectin gene expression at mRNA and protein levels.
Our results showed that IRAK inhibitor and pioglitazone increased the transcription level of adiponectin. Also, adiponectin concentration increased in serum of insulin-resistant mice by IRAK inhibitor and pioglitazone.
In Toll-Like Receptor signaling pathways which are activated by lipids, lipoproteins, lipopolysaccharides, and proteins, MYD88 is complexed with IRAK4 and IRAK1. IRAK4 activates IRAK1. Activated IRAK1 is released from the complex and through a specific signaling cascade, finally activates NF-κB, a key factor in inflammation response, which increases the transcription of some pro-inflammatory cytokines (17, 19) . IRAK inhibitor by suppression of this signaling pathway can induce anti-inflammatory functions (11) and decrease IR which results from inflammation.
There is a negative correlation between BMI and adiponectin concentration so obesity along with its related inflammation decreases adiponectin production (20, 21) . Adiponectin production is controlled by several factors. Pro-inflammatory cytokines that increased in IR, control negatively the production of adiponectin. In contrast, PPARγ increases the expression of adiponectin in adipose tissue (22) . This is compatible with our results that pioglitazone as a PPARγ agonist and IRAK inhibitor as an anti-inflammatory factor increased the level of adiponectin.
Overexpression of IRAK can induce inflammation and decrease adiponectin level. So, it is not surprising that IRAK inhibitor increased adiponectin concentration (23) . However, deletion of the IRAK1 gene can increase insulin sensitivity without any effect on adiponectin level (10) .
HOMA-AD is an insulin sensitivity index, and our results showed that IRAK inhibitor significantly increased the insulin sensitivity with an efficiency completely comparable with pioglitazone. Also, we showed a significant and negative correlation between HOMA-IR and adiponectin levels, suggesting that adiponectin plays a critical role in tolerance of glucose and increase of sensitivity to insulin. Furthermore, adiponectin can act as a predictorof IR, so that increase in adiponectin level, decreases IR, and increase in IR is accompanied by adiponectin decrease.
In our study, pioglitazone and IRAK inhibitor did not show any synergistic or antagonist effect on each other, suggesting that each of them exert their effects in an independent manner. Pioglitazone as a PPARγ agonist increases the expression of adiponectin while IRAK inhibitor increases the adiponectin level by suppression of proinflammatory cytokines (22, 24, 25) .
Adiponectin through increasing of fatty acid oxidation and glucose uptake, increases insulin sensitivity (26) . In addition, adiponectin has antiinflammatory activity and decreases NF.κB dependent inflammation (18) .
In conclusion, IRAK inhibitor increases adiponectin production and secretion from adipocytes. Adiponectin is an insulin sensitizer adipokine and for this reason, it is possible that IR decrease by IRAKi is mediated by adiponectin gene overexpression. IRAK inhibitor efficacy in reducing HOMA-AD is fully comparable with pioglitazone and further studies may lead to its introduction as a new antidiabetic agent.
